medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 3

<< Back Next >>

Ann Hepatol 2006; 5 (3)

Cirrhotic cardiomyopathy

Al HW, Lee SS

Language: English
References: 93
Page: 132-139
PDF size: 106.75 Kb.


Text Extraction

Liver cirrhosis is associated with a wide range of cardiovascular abnormalities. These abnormalities include hyperdynamic circulation characterized by an increase in cardiac output and a decrease in peripheral vascular resistance. Despite the increased cardiac output, impaired ventricular contractility in response to both physiological and pharmacological stimuli has been described. Other cardiac abnormalities include structural changes including enlargement or hypertrophy of different cardiac chambers and electrophysiological changes such as QT prolongation. This constellation of cardiac abnormalities is termed cirrhotic cardiomyopathy. The pathogenic mechanisms of cirrhotic cardiomyopathy are multifactorial and include cardiomyocyte plasma membrane physico-chemical changes, attenuated stimulatory pathways, and enhanced activity of inhibitory systems. Accumulating evidence suggests that cirrhotic cardiomyopathy plays a major role in the pathogenesis of cardiac dysfunction following liver transplantation or transjugular intrahepatic portosystemic shunt placement. Recent research also strongly suggests that cirrhotic cardiomyopathy contributes to the pathogenesis of hepatorenal syndrome, especially following infections such as spontaneous bacterial peritonitis. Treatment of this syndrome remains largely empirical. Successful liver transplantation is thought to improve all the organ-related hemodynamic dysfunctions, including hepatopulmonary syndrome, cerebral hypoperfusion, hepatorenal syndrome, and cirrhotic cardiomyopathy. The prolonged QT interval normalizes following liver transplantation. Thus, liver transplantation appears to be the ultimate treatment for the cardiovascular complications of cirrhosis.


REFERENCES

  1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennnec’s cirrhosis. J Clin Invest 1953; 32: 1025-33.

  2. Abelmann WH, Kowalski HJ, McNeely WF. The hemodynamic response to exersize in patients with Laennec’s cirrhosis. J Clin Invest 1955; 34: 690-5.

  3. Bayley TJ, Segel N, Bishop JM. The circulatory changes in patients with cirrhosis of the liver at rest and during exersize. Clin Sci 1964; 26: 227-35.

  4. Claypool JG. Hemodynamic studies in patients with Laennec’s cirrhosis. Am J Med Sci 1957; 234: 48-55.

  5. Murray JG, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-367.

  6. Gould L, Sharrif M, Zahir M, Lieto MD. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969; 58: 860-8.

  7. Limas CJ, Guiha NH, Lekagui O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Circulation 1974; 49: 755-60.

  8. Caramelo C, Fernandez-Munoz D, Santos JC, Blanchart A, Rodriguez-Puyol D, Lopez-Novoa JM, Hernando L. Effect of volume expansion on hemodynamics , capillary permeability and renal function in conscious, cirrhotic rats. Hepatology 1986; 6: 129-34.

  9. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. Hepatology 1990; 12: 481-5.

  10. Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991; 260: H1912-17.

  11. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989; 151: 530-5.

  12. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-9.

  13. Liu H, Lee SS. Cardiopulmonary dysfunction in cirrhosis. J Gastroenterol Hepatol 1999; 14: 600-8.

  14. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6(suppl 1): s44-52.

  15. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non alcoholic cirrhosis. J Hepatol 1995; 22: 326-332.

  16. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275.

  17. Lunzer MR, Manghani KK, Newman SP, Sherlock SP, Bernard AG, Ginsburg J. Impaired cardiovascular reponsiveness in liver disease. Lancet 1975; 2: 382-385.

  18. Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 1988; 8: 647-651.

  19. Mikulic E, Munoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1983; 34: 56-59.

  20. Ramond MJ, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: Evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol 1986; 21: 191-196.

  21. Finucci G, Desideri A, Sacerdoti D, Bolongnesi M, Merkel C, Angeli P, Gatta A. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-84.

  22. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (London) 1999; 97: 259-67.

  23. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-75.

  24. Gaskari SA, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 329-37.

  25. Moller S, Sondergaard L, Mogelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-8.

  26. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathpphysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.

  27. Perello A, Inserte J, Godoy A, Puigfel Y, Garcia-Pagan JC, Garcia-Dorado D, et al. Cardiac structure and function in experimental intra-hepatic portal hypertension.[abstract] J hepatol 2000; 32: 65.

  28. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munk O, Godtfredsen J. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54: 852-5.

  29. Rector WG, Hossack KF. Pathogenesis of sodium retention complicating cirrhosis: is there room for diminished “effective” arterial blood volume? Gastroenterology 1988; 95: 1658-63.

  30. Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene DL. Vevtricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study. Hepatology 1988; 8: 658-62.

  31. Estruch R, Fernandez-Sola J, Sacanella E, Pare C, Rubin E, Urbano-Marquez A. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995; 22: 532-8.

  32. Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, Melani L, et al . Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-8.

  33. Lewis FW, Adair O, Rector WG. Arterial vasodilatation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 1992; 102: 1024-9.

  34. Spatt SD, Rosenblatt P. The incidence of hypertension in portal cirrhosis: a study of 80 necropsies cases of portal cirrhosis. Ann Intern Med 1949; 31: 479-483.

  35. Hall EM, Olson AY, Davis FE. Portal cirrhosis: clinical and pathological review of 782 cases from 16,600 necropsies. Am J Pathol 1953; 29: 993-1027.

  36. Lunseth JH, Olmstead EG, Forks G, Abboud F. A study of heart disease in one hundred and eight hospitalized patients dying with portal cirrhosis. Arch Inter Med 1958; 102: 405-413.

  37. Ma Z, Miyamoto A, Lee SS. Role of altered ²-adrenergic receptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996; 110: 1191-1198.

  38. Kempler P, Szalay F, Varadi A, Keresztes K, Kadar E, Tanczos E, Petrik J. Prolongation of theQTc-interval reflects the severity of autonomic neuropathyin primary biliary cirrhosis and in other non-alcoholic liver diseases. Z Gastroenterol 1993; 31 (Suppl. 2): 96-8.

  39. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.

  40. Finucci G, Lunardi F, Sacerdoti D, Volpin R, Bortoluzzi A, Bombonato G, Angeli P, et al. Q-T interval prolongationin liver cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart J 1998; 39: 321-9.

  41. Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, Caraceni P, et al. QT interval inpatients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepaticporto-systemic shunt. J Hepatol 2003; 38: 461-7.

  42. Carey EJ, Douglas DD. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. Dig Dis Sci 2005; 50(2): 320-3.

  43. Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239-46.

  44. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002; 36: 513-20.

  45. Silver MA, Maisel A, Yancy CW, McCulough PA, Burnett JC, Francis GS, Mehra MR, et al. BNP Consensus Panel 2004 : A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10(5 Suppl 3): 1-30.

  46. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P,Moreau R, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-3.

  47. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001; 101: 621-628.

  48. Fleming JW, Wisler PL, Watanabe AM. Signal transduction by Gprotiens in cardiac tissue. Circulation 1992; 85: 420-33.

  49. Gilman AG. G-protiens: Transducers of receptor-generated signals. Annu Rev Biochem 1987; 56: 615-649.

  50. Reuter H. Calcium channel modulation by neurotransmitters, enzymes, and drugs. Nature 1983; 301: 569-574.

  51. Gerbes A, Remien J, Jungst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of _2-adrenoceptor in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409-10.

  52. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac β-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994; 267: G87-93.

  53. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on β-adrenergic receptor signaling in rats with cirrhotic cardiomyopathy. J Hepatol 1997; 26: 904-12.

  54. Jaue DN, Ma Z, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997; 25: 1361-5.

  55. Le Grimellec C, Friedlander G, Yandouzi EH, Zlatkine P, Giocondi MC. Membrane fluidity and transport properties in epithelia. Kidney Int 1992; 42: 825-36.

  56. Moreau R, Komaichi H, Kirstetter P, Yang S, Aupetit-Faisant B, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-23.

  57. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-6.

  58. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: G537-44.

  59. Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, Michel T, et al. The role of the NO pathway in the control of cardiac function. J Card Fail 1996; 2(suppl): S141-147.

  60. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006; 12(6): 837-42.

  61. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 1993; 90: 347-51.

  62. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343-50.

  63. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.

  64. Liu H, Song D, Lee SS. Increased nitric oxide synthase expression in aorta of cirrhotic rats. Life Sci 1999; 64: 1753-9.

  65. Sogni P, Smith AP, Gadano A, Lebrec D, Higenbottam TW. Induction of nitric oxide synthase II does not account for excess vascular nitric oxide production in experimental cirrhosis. J Hepatol 1999; 26: 1120-1127.

  66. Van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996; 24: 747-52.

  67. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 118: 937-44.

  68. Ewing JF, Raju VS, Maines MD. Induction of heart heme oxygenase-1 (HSP32) by hyperthermia: possible role in stress-mediated elevation of cyclic 3’: 5’-guanosine monophosphate. J Pharmacol Exp Ther 1994; 271: 408-14.

  69. Tohse N, Nakaya H, Takeda Y, Kanno M. Cyclic GMP-mediated inhibition of L-type Ca2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 1995; 114: 1076-82.

  70. Suematsu M, Ishimura Y. The heme oxygenase-carbon monoxide system: a regulator of hepatobiliary function. Hepatology 2000; 31: 3-6.

  71. Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol 2001; 280: G68-74.

  72. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003; 41: 657-664.

  73. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 2002; 135: 1191-1198.

  74. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832.

  75. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005; 146: 315-323.

  76. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001; 121: 1209-18.

  77. Startzl TE, Demetris AJ, Van Thiel D. Medical progress: liver transplantation. N Engl J Med 1989; 321: 1092-1099.

  78. Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw B, Sassano JJ, et al. Cardiovascular depression secondary to citrate intoxication during orthotropic liver transplantation in man. Anesthesiology 1986; 65: 457-461.

  79. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, Valgimigli M, et al. Systemic and splanchnic hemodynamics changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology 1999; 30: 58-64.

  80. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 10: 1441-1453.

  81. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.

  82. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, Armstrong WF. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with endstage liver disease prior to orthtopic liver transplantation. Transplantation 1996; 61: 1180-1188.

  83. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, Benotti PN. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation :evidence for early postoperative myocardial depression. Chest 1995; 107: 218-224.

  84. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Cesare E, De Castro S, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97(1): 142-8.

  85. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsen the hyperdynamic circulatory state of the cirrhotic patient: Preliminary report of a prospective study. Hepatology 1994; 19: 129-132.

  86. Rodriguez-Laiz JM, Banares R, Echenagusia A, Casado M, Camunez F, Perez-Roldan F, de Diego A, et al. Effects of transjugular intrahepatic portosystemic stent-shunt (TIPS) on splanchnic and systemic hemodynamics and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 1995; 40: 2121–2127.

  87. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, Zozaya JM, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 1995; 21: 986-994.

  88. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunts. Gut (in press)

  89. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalea M, Navasa M, Monescillo A, Albillos A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218.

  90. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003; 38: 1089-1091.

  91. Ruiz-del Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moriera V, Milicua JM, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42(2): 439-47.

  92. Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E, Calchera I, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldesterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005; 100: 1110-1116.

  93. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, Castell J, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74.




2020     |     www.medigraphic.com